AMNIOmics: A Prenatal Rapid Genome Validation Study

NCT05834621 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-09-05

No results posted yet for this study

Summary

The purpose of this study is to validate Whole Genome Sequencing (WGS) on amniotic fluid to reduce the time to diagnosis and enhance the care for the fetus/neonate.

Conditions

  • Multiple Anomalies of Fetus
  • Genetic Predisposition Suspected
  • Amniocentesis Affecting Fetus or Newborn
  • Family Members

Sponsors & Collaborators

Principal Investigators

  • Myra Wick, MD, PhD · Mayo Clinic

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-07
Primary Completion
2025-01-07
Completion
2025-01-07

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05834621 on ClinicalTrials.gov